A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods

M. D. Schluchter, A. F. Barker, R. G. Crystal, R. A. Robbins, J. M. Stocks, J. K. Stoller, M. C. Wu, Z. Bengali, C. E. Vreim, A. Rothgeb, G. L. Snider, K. Detre, H. Y. Reynolds, M. S. Tockman, J. Wittes, A. S. Buist, B. Burrows, A. Cohen, R. J. Fallat

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


The Registry of Patients with Severe Deficiency of Alpha1-Antitrypsin (AIAT) is a multicenter natural history study, with 37 participating clinical centers in the United States (36 centers) and Canada (1 center). The study has enrolled 1,129 individuals aged ≥18 years with severe deficiency of AIAT (serum level ≤11 μM), and will follow them longitudinally for up to 7 years, characterizing the clinical course of the disease, regardless of whether they are receiving augmentation therapy. Primary outcomes of interest are the yearly decline in FEV1 and mortality. This article describes the design and structure of the Registry.

Original languageEnglish (US)
Pages (from-to)1223-1232
Number of pages10
Issue number4
StatePublished - 1994
Externally publishedYes


  • alpha-antitrypsin
  • augmentation therapy
  • decline in lung function
  • design of studies
  • emphysema
  • longitudinal studies
  • registries
  • replacement therapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods'. Together they form a unique fingerprint.

Cite this